Congratulations to Dr. S. Larry Goldenberg on winning the American Urological Society's 2017 Hugh Hampton Young Award. He received this for outstanding contributions in the study and treatment of prostatic diseases, and spearheading the development and implementation of a national men's health program. The Hugh Hampton Young Award has been presented annually since 1969 to an individual for outstanding contri
NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
Dr. Nathan Lack, one of the VPC’s former post-doctoral fellows, has returned to his geographic and academic roots. A Vancouver Coastal Health Research Institute (VCHRI)’s Rising Star in 2011 and a Michael Smith post-doctoral fellow, he has continued to shine across the Atlantic at the exceptionally competitive and highly regarded Koç University School of Medicine in Istanbul, Turkey as an Associate Professor.
Dr. Amina Zoubeidi is the focus of a Nov. 25 article in the Vancouver Coastal Health Research Institute newsletter. Read the full article here (opens in new window).
The VPC's My Precision Oncology Program (MyPOP) is the lead story in the November 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. The article includes an interview with Dr Alexander Wyatt, a Senior Research Scientist at our Centre. Read the full article here (opens in new window)
For the third consecutive year, the University of British Columbia and the Vancouver Prostate Centre’s Prostate Cancer Supportive Care Program participated in the 16th annual Pacific Northwest Prostate Cancer Symposium on Saturday September 24, 2016. This year was Vancouver’s turn to host the symposium for patients, their families and health care professionals, in conjunction with the OHSU Knight Cancer Institute and the University of Washington School of Medicine.
Dr. Michael Cox joined host Dawn Chubai on Breakfast Television this morning, where he was interviewed about prostate cancer and Movember. Watch the 5-minute segment at Breakfast TV's website here (opens in new window, Flash required).
A study lead by Dr. Zoubeidi with a team from the Vancouver Prostate Centre and collaborators at Weill Cornell Medicine has been published online on October 26, in AACR's journal Cancer Discovery.
OncoGenex Pharmaceuticals Inc. has announced positive survival results from the final analysis of the Apatorsen Phase 2 Borealis-2™ trial in metastatic bladder cancer. Apatorsen (OGX-427) was discovered at the VPC and outlicensed to OncoGenex. The full press release is below; click here for the original article on PR Newswire (opens in new window).